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Summary
Thoracic and cardiovascular surgery are innovative specialties that regularly recruit the latest technological developments into their armoury
of devices and equipment. The introduction of new technology is dependant on patents; an important but single component of intellectual
property. Patents enable the attribution of rights to concepts, ideas and inventions and this facilitates ownership, subsequent licensing and
overall management of innovation and its outcome. It is not just thoracic and cardiovascular surgery, but the healthcare world in general that
experiences ongoing technological evolution; so to remain contemporary, it is important that those in positions of responsibility are familiar with
the relevant processes. This requires basic medico-legal knowledge and may be entwined with significant financial responsibility. Penetrating
clinical, academic and industrial environments, informed awareness of patents also contributes to important leadership skills, encouraging the
incorporation of innovation into the professional milieu. We aim to present through this manuscript an overview of these issues in order to
promote awareness of patents within thoracic and cardiovascular surgery using a descriptive and practical approach.
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Patents, a single but essential component of intellectual
property, provide the means through which devices, instru-
ments and equipment can be protected. Multiple levels of
protection exist such as proprietarymanufacturing technology
and combinations of these can strengthen the degree of
protection.Withoutpatents, devices cannotenter themarket-
place without exploitation risk and the owners of the devices
whomay be individuals, universities or hospital trusts may not
benefit from their potential.
Any specialty that attracts regular recruitment of up-to-
date technology, needs a foundation of understanding of
patents and intellectual property. Thoracic and cardiovascular
surgeryareexamples of surgical specialties that dependon the
use of an extensive array of devices and technology. This is to
support the requirement to remain at the forefront of
contemporary surgery such that the best possible health-
care facilities can be delivered. By definition, to remain§ We are grateful for support from the NIHR Biomedical Research Centre
Funding Scheme.
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doi:10.1016/j.ejcts.2008.11.025contemporary necessitates a continuous process of develop-
ment and adoption of evolving technology.
Inventions need to meet specific criteria to be eligible for
a patent which is ‘. . . a contract . . . that grants the patent
holder the right to exclude others from making, using, or
selling the invention for a period of 20 years from the date of
filing of the patent application’ [1].
Patents and their management have inherent advantages
and benefits. One of the most important benefits of patents is
the generation of positive financial return but they themselves
cost money to initiate. Significant revenue may be generated
for the individual, academic organisation and hospital trust.
Patents are now recognised as a professional activity by
academic surgeons and may contribute to their formal
assessment. Successful patent applications also demonstrate
evidence of clinical governance adherence since they can be
used for the purposes of re-validation and self-appraisal. The
potential intellectual recognition and political gain all
contribute to the enhancement of professional reputation
and recognition. Finally, an important function of patents is
that they facilitate the dissemination of technical and
scientific information.
Merging the clinical world with intellectual property and
patents has its disadvantages. Even though there ultimatelyurgery. Published by Elsevier B.V. All rights reserved.
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Table 1
Definitions and key terms in intellectual property.
Invention An invention is a new (previously undiscovered)
method, device, process, algorithm, or tangible
material that can be used for a specific purpose
[Duke University].
Inventor The inventor is the person who thinks of the
invention.
Owner and ownership Ownership is the state or fact of exclusive rights
and control over property, which may be an object,
land/real estate, intellectual property (arguably)
or some other kind of property [Wikipedia].
Trade secret ‘Trade secrets’ are non-patented confidential
ideas.
Innovation Putting the idea into practice.
Copyright A copyright is the exclusive legal right, given to the
originator or their assignee for a fixed number of
years, to publish, perform, film, or record literary,
artistic, or musical material, and to authorize
others to do the same [Oxford Dictionary].
License System through which the owner of intellectual
property enables another person or company to use
the intellectual property.
Trade mark A trade mark is a symbol, word, or words, legally
registered or established by use as representing a
company or product or a distinctive characteristic
or object.
Patent ‘A patent is a contract (from the federal
government) that grants the patent holder the
right to exclude others from making, using, or
selling the invention for a period of 20 years from
the date of filing of the patent application’ [1].may be generation of revenue, patents are burdened with
significant financial responsibility, especially in the early
stages. For this reason, surgical progress often requires
industrial support and clinicians and surgeons need to be
included in these negotiations. Union with the industry may
introduce restrictions on the inventors. The time commit-
ment required is significant andmay impede on the clinician’s
time management balance. It is well recognised that even
armed with prior knowledge, the time consumed through a
patent application is significant, let alone committing further
time to studying the process. Acquiring an understanding of
patents and their legislation is intellectually demanding and
challenges include coping with complex geographical varia-
tions and delicate ethical quandaries.
It is a predictable consequence that the same professionals
that utilise novel technology are often the creators of the
concepts and ideas but they often risk losing ‘ownership’ and
intellectual property rights in the ‘development to manufac-
ture process’ and consequently losing out on the possible
benefits. This may be a result of lack of familiarity with the
processes and potential exploitation by the industry. Though
familiar with the basic concepts of patents, thoracic and
cardiovascular surgeons and clinicians in general may not be
comfortable with the mechanics of their implementation
and furthermore, the experience of ‘patent life’ can vary
significantly with geographical change. It is concerning that
apprehension of the unknown and avoidance of ethical
dilemmas may discourage an attitude of innovation and the
development of novel ideas. This may lead to a negative
impact on the growth of the specialty at a most critical time
when it is established that the face of thoracic and cardi-
ovascular practice must change to adapt to the current era.2. Terms for understanding intellectual property
emphasising patent management
Patent administration integrates many aspects including
an extensive legal framework. Many of the terms used will be
unfamiliar to those with no legal or commercial background.
To begin to understand the practise and management of
patents, even in basic terms, it is essential to comprehend
the language and terminology. A glossary of essential terms
and definitions are presented in Table 1 to facilitate this
understanding and abbreviations are shown in Appendix A.3. Historical aspects of intellectual property and
patents: focusing on Europe and United States
The first surgical procedure was probably trepanation
performed in ancient communities [2] and the first patents,
‘litterae patentes; an open letter’ [3], are thought to have
originated from Ancient Greece and Rome from which there
are reports of protected food recipes [4]. The first recorded
patent was in Florence in 1421. This was followed by a
Venetian statute in 1474 and this heralded the start of
modern European international patent law [5]. It is unclear
when the first medical patent was issued.
In the United Kingdom, King Henry VI issued a ‘letter
patent’ in 1449 [6] and this was followed by formalisation ofpatent laws under the reign of Queen Anne. The ‘letter
patent’ generated the term ‘patent medicine’ which
referred to medicines with secret formulae. In 1852, the
Patent Office was set up and renamed ‘the UK Intellectual
Property Office’ (UKIPO), its current title in 2007 as described
on the UKIPO website [Table 2, Link 1].
Patent law started in the United States in 1802 with the
introduction of a Department of State official, ‘Super-
intendent of Patents’ who dealt exclusively with patents.
In 1836 this was revised to the ‘Commissioner of Patents’.
The Patent Office moved from the Department of State via
the Department of Interior in 1849 to the Department
of Commerce in 1925 where it remains to this day.
Renamed the ‘Patent and Trademark Office’ in 1975 it took
its current name, the ‘United States Patent and Trade-
mark’ Office (USPTO) in 2000. This history of American
Patent law is derived from the USPTO webpage [Table 2,
Link 2].
Historical medical patents of interest include the artificial
limb patented in 1863 and the stethoscope probe in 1864
which are the first recorded patents that we retrieved. The
hypodermic needle was not patented until 1949 [6].
Historical milestones are summarised in Table 3.4. Patent administration and law
The administration of patents is subject to precise
litigation and the application process is fastidious. Common
principles exist globally but geographical differences intro-
duce variation to the implementation processes. The main
principles to consider in themanagement of patents and their
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Table 2
Useful links and web-based references.
1 UK Intellectual Property office (UKIPO) http://www.ipo.gov.uk
2 United States Patent and Trademark Office (USPTO) http://www.uspto.gov/
3 NHS innovations for London http://www.nhsinnovationslondon.com/
4 Confidentiality and confidential disclosure agreements (CDA) http://www.ipo.gov.uk/cda.pdf
5 Patents application guide http://www.ipo.gov.uk/p-apply.pdf
6 FY 2006 U.S. Licensing Survey Activity Survey Summary http://www.autm.net/index.cfm
7 The Chartered Institute of Patent Attorneys’ (CIPA) http://www.cipa.org.uk
8 PACTT Technology Transfer http://www.pactt.ch/
9 Imperial innovations http://www.imperialinnovations.co.uk
10 Patents Act 1977 (as amended) UKIPO http://www.ipo.gov.uk/patentsact1977.pdf
11 World Medical Association Statement on Medical Process Patents www.wma.net/e/policy/m30.htm
12 EU Directive 98/44/EC http://ec.europa.eu/internal_market/indprop/
invent/index_en.htm
13 Patents: Commission adopts a second report on biotechnological
inventions, covering gene patents and stem cells
http://europa.eu/rapid/pressReleasesAction.do?reference=
IP/05/960&format=HTML&aged=0&language=EN&guiLanguage=en
14 World Intellectual Property Organisation http://www.wipo.int/portal/index.html.en
European Union http://europa.eu/index_en.htm
USPTO Fee Schedule http://www.uspto.gov/main/howtofees.htm
European Patent Office http://www.epo.org/
European Patent Office Search page http://ep.espacenet.com/advancedSearch?locale=en_EP
EU Report on Biotechnological Inventions http://europa.eu/rapid/pressReleasesAction.do?reference=
IP/05/960&format=HTML&aged=0&language=EN&guiLanguage=en
Table 3
Critical milestones of patent development.
Ancient Greece/Rome Protected food recipes
1421 First recorded patent, Republic of Florence
1449 ‘letters patent’, King Henry VI, England
1474 Venetian statute
1623 ‘Statute of monopolies’, James I, England
1802 ‘Superintendent of Patents’, United States
1836 ‘Commissioner of Patents’, United States
1852 ‘Patent Office’, United Kingdom
1975 Patent and Trademark Office, United States
2000 United States Patent and Trademark Office,
United States
2007 UK Intellectual Property Office, United Kingdomadministration are evaluation, protection and licensing of
intellectual property [7].5. Evaluation
The first step of evaluation is to establish what the
requirements are of an invention to qualify for a patent. The
requirement is that the invention must be new, involve an
inventive step and be capable of industrial application. Non-
patentable inventions include discoveries, scientific the-
ories, mathematical methods, schemes and the presentation
of information or a computer program as described by ‘NHS
Innovations London’ [Table 2, Link 3].
Once it has been established that the invention qualifies
for a patent, the next step is to assess its patentability. This is
influenced by two key factors; market factors (including the
novelty) and patent issues. Evaluation of the patentability is
best made by experts [8].
It is essential to establish that the idea is novel and has
not already been invented and patented. This market
analysis is ultimately formally performed by the Patent
Office but it is good practise for the inventor to check first.
An ‘infringement clearance search’ (also referred to as a
‘clearance search’) determines the probability of infring-ing on other parties rights. This is quantified by ‘risk’ and
can be a costly exercise when it happens. The procedure is
to perform a search for any relevant publications which are
the same or similar and the purpose is to identify any
potential cross-over with other ideas be it graphical or
literary. Generalised topic searches can be performed
using popular search engines such as Google or PubMed
and every Patent Office provides an on-line search facility
for existing patents, which enables a rapid exclusion of
potential infringement.6. Protection/disclosure
An essential principle in the protection of intellectual
property is discretion and this remains a key theme
throughout the formal development and maintenance of
the intellectual property. It is unanimously established that it
is imperative from the earliest stage to establish confidenti-
ality but there is a delicate balance between confidentiality
and disclosure. Secrecy can be a confounding factor since, on
the one hand lack of confidentiality and idea disclosure will
compromise any future protection of intellectual property
and on the other, the ‘top secret’ approach makes it
impossible to collaborate with colleagues and/or experts so
progress may be restricted and complicated.
Apart from being discrete, there are formal ways of
establishing non-disclosure and this can verify evidence of
‘date of creation’. Non-disclosure implementation varies
geographically. The most basic first line is to keep a close
record of the idea/s as a document with drawings. This should
be signed by the inventor(s), countersigned by a witness and
self-mailed but not opened on receipt. More formal non-
disclosure arrangements are provided by confidentiality
disclosure agreements (CDAs) also known as confidential
agreements or ‘non-disclosure agreements’ (NDAs). These
are recommended when discussing the idea with anyone
other than registered lawyers or patent agents (since
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Fig. 1. (a) UK patent application process. (b) USA patent application process.discussion with these parties is considered safe and legally
privileged). The formal agreements are prepared by lawyers
or patent agents, are legally binding and record the terms
under which secret information is exchanged. The UKIPO
publishes an online PDF booklet for further advice in this area
with an example of a CDA [Table 2, Link 4]. In the United
States, confidential agreements are not essential when
applying for a patent since the initial brief (preferably with
drawings) can be forwarded to the USPTO and this becomes
recognised as a formal ‘disclosure document’. When this
route is taken, the ‘disclosure document’ is filed for 2 years
and may be used to retrospectively provide ‘evidence of the
date of conception of an invention’. Following this, it is
destroyed. Though not recommended, if industrial collabora-
tion is necessary prior to patent proceedings, a CDA should be
used. It is CDAs that enable the existence and recognition of
confidential information, which may be commercially or
technically valuable and bought, sold or licensed. Such
information is designated as ‘know how’ or ‘trade secrets’.
For most medical inventions, the best available protection
is established by the award of a patent although other
protection routes exist. The process of patent application
and administration is governed by very precise law and this
may be complicated by significant geographical variation. For
this reason, individual nations and grouped coalitions of
nations have expressly dedicated government bodies.
Common principles are adhered to although their exact
implementation differs between regions. Early protection of
an idea is unanimously essential and though the processes
may be dissimilar, once secured, the main principles are
patent application (or filing), granting of patents and finally
patent maintenance. We attempt to highlight the main issues
as below.
Completing the patent application varies in implementa-
tion between regions. The basic concept is to convey the
concept or idea to the Patent Office using descriptive text
and illustrative diagrams together with a fee. Justification of
the novelty is included and the document should bewritten in
such a way as to incorporate potential future applications of
the idea. Emphasis should be made to specifically protect
that part of the invention that best secures the owners and
inventors monopoly of that intellectual area.
We will demonstrate some examples by comparing the
application process in the United Kingdom and the United
States (Fig. 1). In the United Kingdom (Fig. 1a) a ‘patent
specification’ is prepared and submitted with Form 1 to the
Intellectual Property Office. This submission which should
include a description claims and abstract generates a receipt
which defines the ‘filing date’. In addition to the text,
drawings should be incorporated which demonstrate how the
invention works and how it is made. ‘Claims’ are sentences
defining the invention and describing technical features.
Form 9A is then submitted which instructs a ‘search request’.
After a ‘preliminary examination’ the application is pub-
lished. A ‘substantive examination’ is requested by submit-
ting Form 10. The Intellectual Property Office examines the
application and if all the requirements of the Patents Act
1977 are met the patent is granted, published and a
certificate is issued. Further detailed information is available
from ‘Patents: Application guide’ published by the UKIPO
[Table 2, Link 5].The process differs in the United States (Fig. 1b) and the
following information is taken from the USPTO website
[Table 2, Link 2]. The first step is to fill in a provisional patent
application and this establishes the ‘filing date’ and permits
the term ‘patent pending’ to be applied in connection with
the invention The requirements are a filing fee and the
inclusion of a cover letter but Claims, Oaths and Declarations
are not required at this stage. A non-provisional application
for a patent request is then submitted to the Director of the
United States Patent and Trademark office. This requires a
written document (written in English or with an English
translation) which includes the specification (description and
claims) and an oath or declaration. In addition a drawing
should be included and the appropriate fee. As in the United
Kingdom claims, the ‘oath’ or ‘declaration’ is the statement
that declares that the inventor believes that he/she is the
‘original and first inventor of the subject matter of the
application’. Declaration forms are available from the USPTO
by mail or Internet.7. Licensing
Licensing describes the system through which the owner
of intellectual property enables another person or company
to use the intellectual property. Licenses can be exclusive,
non-exclusive or sole and the licensor income is generated
though a combination of fixed fees and royalties. Typical
royalties are in the order of 2—5% of sales. It is also possible to
sell the ‘ownership’ of an idea and this is termed an
‘assignment’.8. Multiple layers of protection
Patents provide a method of IP protection which may or
may not be the optimal approach for a specific invention,
especially considering the early financial commitment and
complexities of geographical variation. In addition to
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diverse levels of security. Other tiers of protection are
delivered by copyrights, database rights, registered and
unregistered design rights and trade marks (NHS Innovations
London website [Table 2, Link 3]).
Copyrights are automatic and exist automatically from the
moment the work is completed. They protect the physical
entity (for example written text, photographs, music) but
not the idea. Database rights protect electronically stored
information and design rights protect designs which may or
may not be registered with the designs registry. The trade
mark protects the ‘sign or symbol that allows consumers to
distinguish between different providers’ (NHS Innovations
London website [Table 2, Link 3]).9. Patent development and sources of advice
Apart from fulfilling the legal requirements of patents,
careful consideration must be made as to the overall strategy
that will be recruited in their adoption. Examples of
important early factors to consider include dilemmas of
ownership, financial backing and recruitment of external
specialists. The application process is complicated and it is
unequivocally recommended that the lone inventor seeks
professional assistance and advice.
In the first instance, it is essential and universally
obligatory that health professionals check their local policy
and contact their specific IP representatives since all trusts
and institutions should have an IP policy which is usually
compulsory. (Some trusts may permit the use of independent
agents and independent individuals may secure a private
patent attorney.)
‘Technology transfer’ recruits the assistance of specialists
to develop inventions and links the inventors to the business
world while legal offices facilitate the completion of IP
protection. Formerly, such assistance was ‘externally’
recruited but there has been a shift to setting up internal
technology transfer and legal offices within academic
institutions and universities, especially in the United States.
These offices have in themselves become a growing lucrative
industry and in 2006, US academic centres received $45
billion dollars in R&D expenditures (The Association of
University Technology Managers [Table 2, Link 6]).
In the United Kingdom, ‘medically tailored’ advice is
available through the NHS which provides a web-based
service for inventors — ‘NHS Innovations for London’ [Table 2,
Link 3] and we strongly encourage readers to visit their
website. This organisation provides a wealth of information
on intellectual property and patents specifically for innova-
tive health professionals. They recommend that the research
and development department and/or intellectual property
lead in the inventor’s trust are initially contacted and they
should invariably forward the process to the NHS innovations
hub. There is the provision for their intellectual property
managers to draft an application followed by the recruitment
of a patent attorney to define the claims since this is felt to be
the most cost-effective approach. For general (non-medical)
advice, the UKIPO advises contacting a chartered patent
attorney. Applicants are referred to a list of patent attorneys
and this is available from the Chartered Institute of PatentAttorneys (CIPA). [Table 2, Link 7]. European institutions also
provide technology transfer offices such as PACTT of the
University of Lausanne (PACTT technology transfer website
[Table 2, Link 8]) and Imperial Innovations [Table 2, Link 9])
and the European Union recently issued guidelines on the
management of intellectual property in knowledge transfer
activities [9]. Similarly, in the United States local institutions
have installed well-developed departments which give
advice in IP implementation and maintenance and fulfil
‘technology transfer’ responsibilities. Examples include, the
Mayo clinic [8] and Harvard University (The Association of
University Technology Managers [Table 2, Link 6]) where
there is provision of ‘in house’ expertise, patent attorneys
and ‘collaborative brainstorming’.
Internationally, invention promotion companies also
exist, offering expert services to people wishing to take
out patents. The inventor can work with such companies
but it is important to get independent legal and financial
advice. When contacting such companies it is essential to
maintain a non-disclosure policy until such a time that a
confidentiality agreement is agreed and trust is estab-
lished. Start-up companies require approximately $10—20
million dollars to successfully bring devices from con-
ception to the market-place and this is following several
rounds of financing.10. Influence of geographical variation on patents
Patent implementation and law varies geographically and
inventors need to consider both local and remote IP
protection options. Patents are normally applied for in the
country from which the idea originates; however it is
important to establish more geographically comprehensive
protection. If this is not done, it is hard to defend
manufacturing rights should another party wish to assemble
the product elsewhere. (This is an area where multiple layers
of protection may be especially helpful.)
A facility which helps to address the problem of
geographical cover is the existence of patent treaties. These
legally coalesce geographical zones to enable more region-
ally comprehensive applications. It is possible to submit a
singular standardised application which enters a centralised
filing procedure covering multiple nations. The main treaties
are the patent co-operation treaty (PCT) and the Paris
Convention for the Protection of Industrial Property. The
European patent convention or PCT, conceived in 1970 is
formed by the United Kingdom and 137 other countries
including the United Sates. The Paris Convention for the
Protection of Industrial Property which is adhered to by 168
countries, entitles the citizens of its member states to equal
rights in patent and trade mark matters. It also enables for
right of priority which permits effective retrospective filing
throughout the treaty members to the date of the first
application (USPTO website [Table 2, Link 2]. International
applications can be made via patent conglomerates such as
the European Patent Office (EPO) or the International Bureau
of the World Intellectual Property Office (WIPO) in Geneva
which utilise these treaties.
When trying to achieve increased geographical cover, the
common first step is to apply to the national office of the
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NHS Innovations London websites [Table 2, Links 2 and 3]).
For the United Kingdom, a PCT application should be
submitted within 12 months of the UKIPO filing and this can
be done via EPO or WIPO. Akin to the United Kingdom, to
achieve IP protection in another country, the American
inventor needs to apply directly to that country or via a
regional Patent Office since United States patents only cover
the United States (USPTO and NHS Innovations London
websites [Table 2, Links 2 and 3]).
It is essential to get the time schedule right since patents
will not be awarded if there is publication of the invention
prior to the application date (unless the application is
through an international treaty). Furthermore, there is
stipulation that the invention is manufactured in the country
from which IP protection extension is requested and failure
to do so may nullify the patent if it has been awarded. In
addition, if a non-US patent is applied for a US invention
before or within 6 months of a US patent, a license must be
granted from the director of the USPTO (USPTO website
[Table 2, Link 2]).
For multi-national applications, the searches are carried
out by the International Search Authority and the Interna-
tional Bureau publishes the patent application. After
publication, an international preliminary examination is
requested. It is important that the ‘national phase’ is entered
in each country prior to the deadline which is usually 31
months after the priority date (USPTO and NHS Innovations
London websites [Table 2, Links 2 and 3]). To achieve
worldwide cover is not economically feasible since there are
around 200 states and the cost would be astronomical.
Usually, 20—30 states are covered prioritising them econom-
ically and marketwise. This generates a cost of at least
$200,000.
The WIPO Patent report of 2007 has demonstrated very
high growth rates in the use of the patent system in north east
Asian countries especially in the Republic of Korea and China.
The distribution of worldwide patents is varied with Japan
and the United States receiving the greatest number of
patent applications. Source: the WIPO Report, 2007 edition.11. Owner versus inventor?
It is important to clarify who is the owner and who is the
inventor since these roles have different implications with
important variable financial outcomes. The inventor is the
person who has the idea whereas the owner is the person or
body that control the property. The owner holds the
intellectual property rights but the inventor is only nominally
accredited with the invention and essentially otherwise
powerless over its administration. In the application process
for patents there is scope to separate these roles and an
application can have more than one inventor.
In the United Kingdom, the National Health Service (NHS)
trusts own all intellectual property generated by their
employees in the course of their employment as described in
the Patent Act of 1977 which is available on line via the UKIPO
[Table 2, Link 10]. The ‘inventor’ is recognised in that
capacity but the trust takes ownership. In this respect, trusts
are encouraged to develop a revenue sharing scheme.An example of a revenue sharing scheme is that employed
by CHUV, the University Hospital of Lausanne which after
patent costs keeps 10% for PACTT and distributes 30% to the
inventor, 30% to the unit and 30% to the institution (PACTT
Technology Transfer [Table 2, Link 8]).
In Spain, ‘Superior de Investigaciones Cientı´ficas’ (CSIC),
the Spanish National Research Council, owns research
patents but new legislation permits an equal revenue sharing
scheme between inventors, the council and the institution or
company to which the inventor belongs [10].
In theUnited States, the situation is nowdifferent. As in the
United Kingdom, the federal government retained patent
ownership until the owner inventor relationship in academic
universities and institutions was radically re-addressed
through the introduction of the Bayh-Dole act in 1980. Through
stating that ‘the control of intellectual property generated by
federal funding is granted to the universities and other
nonprofitorganisationswhichusedthe funding for the research
that led to the discovery’ [11] the ownership is retained by the
recipients of federal funding and as in the UK, most univer-
sities/institutions specify that aportionof the rewardsmustbe
returned to the school. [12] The Bayh-Dole act has promoted
the development of inventions and their commercialisa-
tion. Specific IP procedures are region/institution/affiliation
exclusive and there are therefore differing agreements.12. Entering the market-place
Apart from securing IP legal protection, when bringing
inventions to the market-place, there are several important
factors which must be considered. These include the relation-
ship between patent development, commercialisation and
industrial collaboration, models of technological innovation,
recruitment of financial assistance, adherence to compulsory
regulatory routes and the timing of IP protection. These topics
are broad and complex, rendering them beyond the remit of
this paper.13. Costs and fees
Patent applications are costly and the amounts vary
internationally. Initially there is a filing and application fee
followed by ongoing maintenance fees which are substantial.
The greater the domain covered, the greater the costs. We
illustrate using the United Kingdom and United States fee
schedules.
In the United Kingdom filing forms with the UKIPO requires
fees. Form 9A costs $225 US dollars (£130) which includes
$175 US dollars (£100) for the search and $50 US dollars
(£30) for the application fee. Form 10 costs a further $120 US
dollars (£70) for the substantive examination. In addition
patent attorney fees are charged quantitatively on a time
basis. The overall cost is dependant on the complexity of the
patent. An average complete UK based patent costs $5240—
8730 US Dollars (£3000—5000) (NHS Innovations London
website [Table 2, Link 3]). The cost of applying for and
securing a United States patent is >$20,000. The United
States Fees Schedule is complicated and difficult to
summarise. It may be downloaded from the USPTO
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can be at least 10 times greater [8].14. Duration and timeline
A patent usually takes 2—3 years to grant. The procedure
can be fast-tracked on request and maximally take four and a
half years. The patent lasts 20 years from the time of filing.15. Ethical considerations for healthcare patents
Introduction of intellectual property into the healthcare
worldandunionwithcommerce inevitably bringsaboutethical
anxiety. Regardless of the area being deliberated, when
applying for healthcare patents the incorporation of ethical
consideration is of paramount importance. It is necessary to
contemplate healthcare patents in well defined groups (for
example; devices, procedures and biotechnology) since
differing medical areas oblige distinct ethical principles.
The balance between the advantages and disadvantages
of medical patents must be carefully considered since
difficult dilemmas such as conflicts of interest, concern of
inhibition of dissemination of knowledge and the conflict of
personal gain versus patient benefitmay be unconstructive to
patient management and this remains the main concern.
Medical device patents are considered permissible and
ethical on an international level. ‘Medical and Surgical
Procedure Patents’ or ‘Medical Procedure Patents’ are
permitted in the United States which is of special interest
to surgeons, whereas they are not in Europe and the United
Kingdom. Such patents are inclusive of surgical technique. The
notion was challenged in 1996 in the case of Pallin v Singer,
where Dr Pallin failed to enforce patent claims on a specific
incision used in cataract surgery [13,14]. ‘Medical Procedure
Patents’ remain permissible despite non-favourable argu-
ments issued by the Council on Ethical and Judicial Affairs
(CEJA) of the American Medical Association [15,16]. In fact,
United States Medical process patents issued since 1996 have
not been enforceable against those infringing upon them
through performing a medical or surgical procedure and this
renders them practically meaningless. The World Medical
Association position on Medical Procedure Patents issued in
1999 [Table 2, Link 11] expresses concern that such patents
may limit the availability of new procedures to patients and
considers such patents unethical.
This is of interest in the context of surgical specialties
since in principle it is possible to patent a technique,
especially if it includes the use of a medical device which is a
common scenario in cardiovascular surgery. It is noted that
this information has either not diffused into practise or is not
actioned for legitimate ‘other’ reasons since to our knowl-
edge there have been no attempts to intellectually protect
traditional cardiovascular surgical techniques such as the
implantation of valves.16. New challenges and frontiers
It has been established that it is possible to patent devices
and the process is tried and tested, but ongoing scientificdevelopment in novel areas has obliged the introduction of
new IP frontiers. A key growth area is that of biotechnology
which presents an entirely different IP challenge with
consequent complex litigation. This is relevant since stem
cell technology has entered the thoracic and cardiovascular
experimental and clinical forum. For example, the use of
transplanted tissue engineered cell sheets to seal lung air
leaks and new areas of cardiac surgical research which are
demonstrating that introduction of stem cells by different
routes results in observed cardioprotection [17,18].
Patents have been successfully applied for in this domain.
Bergman et al. state that there has been a recent increase in
the number of patent filings in stem cells and they have
shown that the European Patent Office has received 560
publications and granted 421 patents covering ‘uses,
methods, or compositions involving human or animal stem
cells’ and the USPTO has received 3711 applications and
granted 1724 patents [19].
Biotechnological IP management is managed differently in
Europe and the United States. In Europe, the litigation is
directed by the European Union. To address biotechnological
inventions (stem cells and regenerative medicine), the
European Commission issued Directive 98/44/EC [Table 2,
Link 12]. This was further revised with a second report in 2005
which is the last update we could find on searching the
European Commission Internet site [Table 2, Link 13]. The
report essentially highlighted the difference between
totipotent stem cells and pluripotent embryonic cells. The
former were deemed unequivocally un-patentable since they
have the capability of developing into a human being. The
latter are still under review. However, in the United States,
the picture is very different and controversial, dating back to
patents awarded to the Wisconsin Alumni Research Founda-
tion (WARF) in the 1990s which claim all primate and human
embryonic stem cell lines [19].17. Current trends and examples of patents in thoracic
and cardiovascular surgery
Thoracic and cardiovascular surgery are key examples of
surgical specialties that require a vast array of equipment.
As surgical possibilities develop so must technology
follow and as a result, there exists a wealth of thoracic
and cardiovascular surgical devices. This remains a rapidly
growing area. A single example is the relatively recent
introduction of surgical ablation for atrial fibrillation into
cardiac surgical practice which has brought with it a wide
variety of new devices to enable implementation of this novel
surgical technology.
We performed a search of international patents using key
cardiothoracic and cardiovascular terms and demonstrate
these findings in Fig. 2a. Key terms searched for were:
cardiac surgery; heart surgery; coronary surgery; thoracic
surgery; lung surgery, chest surgery; cardiovascular surgery,
cardiothoracic surgery, heart valve, heart cannula, heart
retractor and coronary anastomosis via the UKIPO, World
Intellectual Property Organisation [Table 2, Link 14] and
USPTO. The search was conducted between 21st May and 6th
October 2008 and demonstrates the key area of heart valve
technology. Our search strategy is exemplified by the term
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Table 4
Diversity of cardiothoracic equipment and devices.
General Scalpels Skin, artery
Diathermy Monopolar, bipolar
Saw Sternal saw
Access Retractors
Ports
Minimally invasive
Procedural CABG Anastomotic devices
Aortic and venous cannulae
OPCAB devices
Robotic equipment
Valves Mechanical, bioprosthetic
Rings (annuloplasty bands)
Robotic equipment
Ablation Ablation devices
Assist devices
Closure Bone closure Wires, sternal clips
Skin closure suture, staples, glues
Aftercare Drains
Dressings
Miscellaneous CPB Perfusion pumps
Perioperative imaging Ultrasound, probes, TOE
Glues and sealants
Monitors
Fig. 2. (a) Worldwide patent search for cardiothoracic terms. WIPO: World
Intellectual Property Organisation; UKIPO: United Kingdom Intellectual Prop-
erty Office; USPTO: United States Patent and Trademark Office. (b) Number of
worldwide patents for ‘cardiac AND surgery’ searched for via British Intellec-
tual Property Office from 1977 to 2007.‘cardiac surgery’. The WIPO search was entered as
‘cardiac_surgery’ and ‘all fields’ were searched. The UKIPO
search was constructed by searching for ‘cardiac and surgery’
limited to ‘words in the title or abstract’ and for the
‘worldwide database’. The USPTO search term was ‘cardiac
surgery’ for ‘all fields’ from ‘1976 to present’. As seen in the
figure, searching the international database for the same
terms revealed a significant discrepancy in numbers between
the results of searches via the different nationality based
search engines. Furthermore, we identified that searching
for cardiothoracic related patents can be unreliable. This is
demonstrated by the search term ‘cardiac surgery device’
which revealed only 1 patent via WIPO, 73 via the UKIPO and
none via USPTO. This clearly underestimates the data and
reinforces the notion that extreme caution must be taken
when searching for patents.
In addition, we searched the international patent
database for the terms ‘cardiac AND surgery’ via the UKIPO
search function [Table 2, Link 1]. This demonstrates a
dramatic increase in the number of cardiothoracic patents in
the last 10 years (Fig. 2b).
This search demonstrated the wide scope of thoracic and
cardiovascular patents when searching for related patents in
general terms but even within the specialty, examples shown
in Table 4 demonstrate the broad potential for devices.18. Discussion
It is established that it is important to remain contem-
porary in medical and surgical practise such that the best
available interventions and treatments are offered and
available. We have discussed how the adoption of technology
requires the practise and application of IP. Once an idea is
created, there is a massive amount of territory to be covered
prior to the physical development of a real device that can be
safely introduced into the market-place.
The first hurdle is that of confidentiality. It is prudent to
maintain this at all times and as discussed there are formal
and informal ways of enforcing this. Following the successful
institution of non-disclosure, further challenges and their
interaction are encountered that can be thought of as
‘internal’ and ‘external’ factors. ‘Internal factors’ relate to
the individual with the idea. In developing innovation and
acquiring intellectual property the key for the individual is to
demonstrate knowledge and awareness of the processes and
systems used to protect IP. Utilisation and practise of
innovative and leadership skills also contribute significantly.
‘External’ factors include all non-self entities. This includes
peers and colleagues, the trust or hospital, the university or
academic institution, legal and technology transfer offices,
ethical institutions and the Patent Offices. Liaison with these
groups is inevitable, essential and introduces an interesting
dichotomy. The key principle is to limit exposure and sharing
of knowledge to only ‘essential’ parties and formalise as
much as possible the confidentiality agreements.
Combining healthcare and the commercial world through
the use of IP inevitably introduces delicate ethical issues. The
main concern is to protect any potential threat of
compromised patient care. Potential challenging influences
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personal gain. A balance between protection issues and
patient care must be found in favour of goodmedical practise
such that patient care never suffers as a result of com-
mercialisation and business development.
To facilitate these potential pitfalls, the relation between
the inventors and the commercial world via academic
institutions and trusts are well defined and often managed
by specific departments such as technology transfer offices
and university legal offices.
Taking thoracic and cardiovascular surgery as examples,
these are surgical specialties undergoing significant change.
For example, in cardiac surgery, the bulk of cases were
historically coronary revascularisations, but routine practise
has grown to encompass several other cardiothoracic opera-
tions. When there is surgical evolution, technological devel-
opmentmust progress equally fast to support it. It is therefore
a natural consequence that new ideas and devices are
continuously being introduced. These ideas require intellec-
tual property protection and patent management. An under-
standing of patents and their ramifications should facilitate
the modern day thoracic and cardiovascular surgeon in their
practice and encourage ongoing surgical development.
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Appendix A. List of abbreviationsCDA Confidentiality disclosure agreement
CSIC Superior de Investigaciones Cientı´ficas
CEJA The Council on Ethical and Judicial Affairs*CIPA The Chartered Institute of Patent Attorneys
EC European Commission
EPO European Patent Office
EU European Union
IP Intellectual property
NDA Non-disclosure agreement
NHS National Health Service
UKIPO United Kingdom Intellectual Property Office
USPTO United States Patent and Trade Office
WIPO World Intellectual Property Organisation
WMA World Medical Association* Of the American Medical Association.
